Pharma companies can have an “emerging markets strategy” Emerging markets are nothing like one another: an Argentinian denied an expensive new drug will usually just go and get a court to order his insurer or the state to pay for it; an Indonesian may never even find out what’s wrong with him. Argentina spends about $1050 per person on … [Read more...] about Five myths about access to medicines in emerging markets
access to medicines
UK parliamentary report on R&D for neglected diseases focuses on …. medieval Venice
This summer, an All Party Parliamentary Group (APPG) on Tuberculosis of the UK Parliament produced a report on research and development for diseases that affect poor people. This was admirable, except that the report has little to do with global health R&D and instead concentrates on radical changes to the system of patents and intellectual … [Read more...] about UK parliamentary report on R&D for neglected diseases focuses on …. medieval Venice
Indian delight over US decision on Samsung #patents – impact on #accesstomedicine
There is widespread delight in India over last week's decision by President Obama to veto a patent ruling that would have disadvantaged Apple and favoured Samsung. The ruling would have stopped Apple from selling some older iPhones in the USA on the grounds that they infringed Samsung's patents. The US based its decision to over-rule the … [Read more...] about Indian delight over US decision on Samsung #patents – impact on #accesstomedicine
The Three Commitments
Why Consultants end up not telling the truth
The worst kind of market research interviewing technique ever
Why bright people can’t explain themselves
